SCHEMBL2248771

SCHEMBL2248771

CC(C)(Cc1ccc(F)cc1)N[C@@H](CCC(N)=O)C(=O)OC(=O)c1ccc(-c2ccc(F)c(F)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.44
MMP8 P22894 1/20 0.44
MMP12 P39900 1/20 0.44
ADAMTS5 Q9UNA0 1/20 0.44
RAB9A P51151 1/20 0.35
BCL9 O00512 2/20 0.35
CTNNB1 P35222 2/20 0.35
PTPN1 P18031 1/20 0.34
ADRB1 P08588 3/20 0.34
ADRB3 P13945 3/20 0.34
ADRB2 P07550 2/20 0.34
PRSS1 P07477 1/20 0.33
TMPRSS15 P98073 1/20 0.33
CETP P11597 2/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
DPP4 P27487 1/20 0.32
KLKB1 P03952 2/20 0.32
CASR P41180 1/20 0.32
CHRNA1 P02708 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2249892 0.94 MMP2 (0.49) MMP2MMP8MMP12ADAMTS5RAB9A
SCHEMBL2247595 0.93 MMP2 (0.43) MMP2MMP8MMP12ADAMTS5ADRB1
SCHEMBL2247537 0.93 MMP2 (0.42) MMP2MMP8MMP12ADAMTS5RAB9A
SCHEMBL2248057 0.92 MMP2 (0.43) MMP2MMP8MMP12ADAMTS5ADRB1
SCHEMBL2254236 0.91 MMP2 (0.47) MMP2MMP8MMP12ADAMTS5ADRB1
SCHEMBL2242489 0.91 MMP2 (0.46) MMP2MMP8MMP12ADAMTS5ADRB1
SCHEMBL2247684 0.91 MMP2 (0.45) MMP2MMP8MMP12ADAMTS5CETP
SCHEMBL2251636 0.89 MMP2 (0.42) MMP2MMP8MMP12ADAMTS5RAB9A
SCHEMBL2253117 0.87 MMP2 (0.46) MMP2MMP8MMP12ADAMTS5ADRB1
SCHEMBL2250802 0.87 MMP2 (0.41) MMP2MMP8MMP12ADAMTS5RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US claimed
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP claimed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 MMP2 49/4885MMP8 70/4885MMP12 54/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 MMP2 49/4885MMP8 70/4885MMP12 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.